Cargando…
Association between chemotherapy response and rate of disease progression in disseminated melanoma.
Fifty-five evaluable patients with disseminated malignant melanoma were treated with the combination of dacarbazine (DTIC) 400 mg i.v. on days 1 to 3 and lomustine (CCNU) 50 to 80 mg m-2 orally on day 1 with intervals of 6 weeks as the first line chemotherapy. Three (5%) patients had complete and 6...
Autor principal: | Joensuu, H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971663/ https://www.ncbi.nlm.nih.gov/pubmed/1989656 |
Ejemplares similares
-
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994) -
Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
por: Newlands, E. S., et al.
Publicado: (1976) -
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
por: Currie, G. A., et al.
Publicado: (1975) -
Loxl3 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival
por: Vázquez-Naharro, Alberto, et al.
Publicado: (2022) -
NAADP-Dependent Ca(2+) Signaling Controls Melanoma Progression, Metastatic Dissemination and Neoangiogenesis
por: Favia, Annarita, et al.
Publicado: (2016)